Travere Therapeutics’ $200 Million Public Offering of Common Stock and Pre-Funded Warrants

Pietro Martinoia
Tagged:

Cooley advises Travere Therapeutics, and Latham & Watkins advises the underwriters.Travere Therapeutics, Inc. (Nasdaq: TVTX) has announced the pricing of an underwritten public offering of 8,275,000…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Pietro Martinoia

…

This content is for Standard 1 Year members only.
Login Join Now